Posted on 1/06/2026
Worthing, UK | 1 June 2026 Rayner today announced the strategic expansion of its surgical offering with the launch of Ophteis Cohesive, a proprietary new Ophthalmic Viscosurgical Device (OVD) developed and manufactured at its state-of-the-art European biomaterials facility. Formulated with a high molecular weight for excellent viscosity and cohesiveness, Ophteis Cohesive demonstrates comparable space creation
Posted on 9/03/2026
Rayner today announced the expansion of its United States headquarters with the opening of a new 10,000 sq. ft. facility in Memphis, Tennessee, reinforcing the company’s commitment to the US as a central pillar of its global growth strategy. Memphis has served as Rayner’s US base for six years and remains a strategically positioned national
Posted on 27/02/2026
Australian cataract patients can now gain broader access to next-generation lens technology, after Rayner secured Medical Device and Human Tissue Advisory Committee (MDHTAC) acceptance and Prostheses List (PL) reimbursement for RayOne Galaxy, effective 1 March 2026. RayOne Galaxy is the world’s first spiral IOL, representing a significant advancement in premium lens replacement technology. Developed with
Posted on 2/02/2026
When patients leave a consultation, they forget 80% of what they were told within 24 hours1 – and when critical information doesn’t stick, ophthalmology clinics are left managing anxious patients and a high administrative burden. eyejourney is the solution. Launching today, eyejourney is a personalised, AI-powered patient education platform designed to bring clarity, consistency and
Posted on 14/01/2026
Rayner has secured US Food and Drug Administration (FDA) 510(k) clearance for Sophi, the Swiss-engineered phacoemulsification system set to redefine efficiency for US cataract surgeons. Sophi (Swiss Ophthalmology Innovation) brings a bold new philosophy to the operating room: maximum productivity, without compromise. Packed with features tailored to meet the demands of ASCs, office-based surgery and
Posted on 13/10/2025
FDA approval expands US access to award-winning lens technology Rayner today announced that the US Food and Drug Administration (FDA) has approved its RayOne EMV Toric intraocular lens (IOL) following the successful completion of a pivotal Investigational Device Exemption (IDE) study. The lens is now available to US surgeons seeking to deliver high quality visual
Posted on 15/09/2025
15 September 2025 | Worthing, UK The results of a landmark study comparing hydrophilic and hydrophobic intraocular lenses (IOLs), presented at the 2025 ESCRS Congress, has confirmed both IOL materials can be clinically and statistically equivalent in preventing posterior capsular opacification (PCO). The safety of hydrophilic IOLs compared to hydrophobic IOLs has been a subject
Posted on 6/05/2025
6 May 2025 Rayner, a global provider of solutions for cataract surgery and the only manufacturer of intraocular lenses (IOLs) in the UK, proudly announces today that it has been honoured with the prestigious King’s Award for Enterprise 2025 for its innovative RayOne EMV increased range of focus IOL. RayOne EMV, which launched in 2020,
Posted on 2/04/2025
02 April 2025 | In response to demand growth, Rayner – a global leader in solutions for cataract surgery – has completed an extensive expansion of its Worthing (UK) production facility, doubling the number of intraocular lenses (IOLs) it can manufacture annually to 4 million. Since opening its purpose-built manufacturing facility in 2017, every Rayner
Posted on 25/03/2025
In a major step toward redefining postoperative care and elevating patient experience, Rayner – a global leader in cataract surgery products – proudly announces the successful completion of its pivotal U.S. dropless cataract surgery study. OMIDRIA (phenylephrine and ketorolac intraocular solution 1% / 0.3%) is the only FDA-approved NSAID for use during cataract surgery, indicated